D.E. Shaw & Co
AMRX icon

D.E. Shaw & Co’s Amneal Pharmaceuticals AMRX Stock Holding History

D.E. Shaw & Co’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$21.4M Sell
1,719,954
-941,900
-35% -$12.6M 0.01% 1099
2025
Q4 		$33.5M Buy
2,661,854
+1,096,643
+70% +$12.5M 0.02% 931
2025
Q3 		$15.7M Buy
1,565,211
+641,567
+69% +$5.76M 0.01% 1347
2025
Q2 		$7.47M Buy
923,644
+907,808
+5,733% +$6.84M 0.01% 1723
2025
Q1 		$133K Buy
+15,836
New +$132K ﹤0.01% 3990
2024
Q3 		– Sell
-89,895
Closed -$571K – 4510
2024
Q2 		$571K Sell
89,895
-136,309
-60% -$865K ﹤0.01% 3544
2024
Q1 		$1.37M Sell
226,204
-439,832
-66% -$2.48M ﹤0.01% 2892
2023
Q4 		$4.04M Sell
666,036
-208,880
-24% -$930K ﹤0.01% 2081
2023
Q3 		$3.69M Buy
874,916
+252,690
+41% +$942K ﹤0.01% 2088
2023
Q2 		$1.93M Sell
622,226
-7,883
-1% -$16.8K ﹤0.01% 2650
2023
Q1 		$876K Sell
630,109
-58,728
-9% -$117K ﹤0.01% 3246
2022
Q4 		$1.37M Buy
688,837
+427,987
+164% +$959K ﹤0.01% 3223
2022
Q3 		$527K Buy
260,850
+71,923
+38% +$202K ﹤0.01% 4013
2022
Q2 		$601K Sell
188,927
-65,072
-26% -$236K ﹤0.01% 3994
2022
Q1 		$1.06M Buy
253,999
+95,977
+61% +$425K ﹤0.01% 3868
2021
Q4 		$757K Buy
158,022
+139,980
+776% +$698K ﹤0.01% 4143
2021
Q3 		$96K Buy
+18,042
New +$90.8K ﹤0.01% 4721
2021
Q2 		– Sell
-122,774
Closed -$826K – 4733
2021
Q1 		$826K Buy
+122,774
New +$680K ﹤0.01% 3243
2020
Q1 		– Sell
-224,285
Closed -$1.08M – 3898
2019
Q4 		$1.08M Buy
224,285
+125,081
+126% +$435K ﹤0.01% 2928
2019
Q3 		$288K Sell
99,204
-59,475
-37% -$208K ﹤0.01% 3486
2019
Q2 		$1.14M Sell
158,679
-265,301
-63% -$2.71M ﹤0.01% 2601
2019
Q1 		$6.01M Sell
423,980
-378,882
-47% -$5.01M 0.01% 1430
2018
Q4 		$10.9M Buy
802,862
+56,890
+8% +$1.03M 0.02% 1037
2018
Q3 		$16.6M Sell
745,972
-246,020
-25% -$5.18M 0.02% 864
2018
Q2 		$16.3M Buy
+991,992
New +$17.4M 0.02% 836

Other funds holding AMRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

D.E. Shaw & Co's AMRX Position: Q1 2026 in Review

D.E. Shaw & Co reduced its Amneal Pharmaceuticals (AMRX) stake by 35% in Q1 2026, selling an estimated $12.6M and leaving 1,719,954 shares worth $21.4M. The position accounts for 0.01% of the portfolio, ranked #1099.

D.E. Shaw & Co first reported a position in AMRX in Q2 2018 and has held it in 25 quarters since. The position peaked at $33.5M in Q4 2025. 315 funds tracked by Wall St. Rank hold AMRX as of Q1 2026.

  • D.E. Shaw & Co held 1,719,954 shares of Amneal Pharmaceuticals worth $21.4M as of Q1 2026.
  • D.E. Shaw & Co sold 941,900 Amneal Pharmaceuticals shares in Q1 2026, an estimated $12.6M.
  • Amneal Pharmaceuticals made up 0.01% of D.E. Shaw & Co's portfolio in Q1 2026, its #1099 holding.
  • D.E. Shaw & Co first reported a position in Amneal Pharmaceuticals in Q2 2018 and has held it in 25 quarters since.
  • D.E. Shaw & Co's Amneal Pharmaceuticals position peaked at $33.5M in Q4 2025.
  • 315 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q1 2026.

Based on D.E. Shaw & Co's 13F filing for Q1 2026, filed 15 May 2026.